Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes.
An economic analysis was conducted using clinical outcomes in the MIRACL trial that evaluated high-dose atorvastatin versus placebo for 16 weeks after acute coronary syndrome. The direct cost of atorvastatin was largely offset by the associated decrease in cardiovascular events. The net incremental cost of atorvastatin treatment was 157 dollars/patient with a cost-effectiveness ratio of 4,086 dollars/event avoided.
Veterans Administration Medical Center and University of Colorado Health Sciences Center, Denver, Colorado 80220, USA. gregory.schwartz@med.va.gov
Gregory G
GG
Schwartz
Peter
P
Ganz
David
D
Waters
Steve
S
Arikian
D000208:Acute Disease; D000789:Angina, Unstable / Q000191:economics / Q000209:etiology / Q000517:prevention & control; D000069059:Atorvastatin; D003362:Cost-Benefit Analysis; D017850:Economics, Pharmaceutical; D017048:Health Care Costs; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000191:economics / Q000209:etiology / Q000517:prevention & control; D017202:Myocardial Ischemia / Q000150:complications / Q000191:economics / Q000517:prevention & control*; D011758:Pyrroles / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D055502:Secondary Prevention; D013577:Syndrome
D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin